Cardiol Therapeutics (TSE:CRDL) has released an update.
Cardiol Therapeutics has successfully completed the MAvERIC Phase II study for recurrent pericarditis, with promising results showing significant reductions in pain and inflammation to be presented at the American Heart Association Scientific Sessions 2024. The company’s drug, CardiolRx™, offers a new non-immunosuppressive treatment option for chronic inflammatory heart disease, potentially improving the quality of life for thousands of patients. With the study’s completion, Cardiol Therapeutics aims to progress to a Phase III trial, underscoring its commitment to addressing the unmet needs in heart disease treatment.
For further insights into TSE:CRDL stock, check out TipRanks’ Stock Analysis page.
